---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-011072"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:35:20.277396+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anteris reaches 100 patients treated with DurAVR THV; strong one-year safety and efficacy data

## Summary
- Over 100 patients treated with DurAVR THV, including de novo, valve-in-valve, and bicuspid cases.
- 65 patients completed 30-day primary endpoints; safety and efficacy demonstrated.
- One-year data on 37 patients shows sustained large effective orifice areas and low mean pressure gradients.
- No valve or cardiovascular mortality at one year; excellent safety profile.
- Pivotal trial on track to commence Q3 2025, pending FDA approval.

## SEC filing metadata
- accession: 0001140361-25-011072
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125011072/0001140361-25-011072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125011072/ef20046399_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-011072
- JSON: https://secwatch.observer/filing/0001140361-25-011072.json
- Plain text: https://secwatch.observer/filing/0001140361-25-011072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.